Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stem cell therapy for kidney disease: Five-Year safety watch

NCT ID NCT05096182

Knowledge-focused Sponsor: Pharmicell Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

Researchers are following 10 people with chronic kidney disease who received Cellgram-CKD, a stem cell therapy, in an earlier trial. Over five years, the team tracks deaths, new cancers, immune reactions, and other delayed problems tied to stem cell treatment. The goal is to learn whether the therapy causes harm much later, not to test whether it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cellgram-CKD, a stem cell therapy made from the patient's own bone marrow
What this could lead to
If the therapy proves safe over years, it could support further testing of stem cell treatment for chronic kidney disease.
What could go wrong
This is a small follow-up of 10 people who already received the therapy, so it can only detect safety signals, not whether the treatment works. Rare delayed effects may still go unnoticed.
Why investors are watching

Pharmicell's Cellgram-CKD was given to patients with chronic kidney disease in an earlier study, and this follow-up tracks 10 of them for five years to check long-term safety. For a small company, that safety record can support later trials or partnering talks, so the readout carries weight beyond its small size.

If it works: A clean five-year safety record may make it easier for Pharmicell to run larger studies or find a partner for Cellgram-CKD.

If it fails: New safety problems in these 10 patients could slow or stop the program, and long follow-up studies often take years to report anything.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

10 people

The number who actually took part.

Started

Mar 2022

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with chronic kidney disease who participated in the PMC-P-12 clinical trial, among those who received Cellgram-CKD, those who agreed to participate in this long-term follow-up study

Ages

19 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Those who participated in the PMC-P-12 clinical trial and received Cellgram-CKD * Subjects who consented in writing to this long-term follow-up study Exclusion Criteria: * Not Applicable

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease

Contacts and locations

Locations

  • Asan Medical Center Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.